Samlyn Capital, LLC Corvus Pharmaceuticals, Inc. Transaction History
Samlyn Capital, LLC
- $6.21 Billion
- Q3 2024
A detailed history of Samlyn Capital, LLC transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, Samlyn Capital, LLC holds 4,530,333 shares of CRVS stock, worth $23.6 Million. This represents 0.39% of its overall portfolio holdings.
Number of Shares
4,530,333
Previous 6,123,021
26.01%
Holding current value
$23.6 Million
Previous $11.1 Million
114.66%
% of portfolio
0.39%
Previous 0.2%
Shares
6 transactions
Others Institutions Holding CRVS
# of Institutions
73Shares Held
30.4MCall Options Held
1.06MPut Options Held
84.3K-
Orbimed Advisors LLC San Diego, CA6.94MShares$36.2 Million0.86% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct5.56MShares$29 Million0.08% of portfolio
-
Adams Street Partners LLC Chicago, IL3.28MShares$17.1 Million10.6% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.42MShares$12.6 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA1.5MShares$7.8 Million1.16% of portfolio
About Corvus Pharmaceuticals, Inc.
- Ticker CRVS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,553,500
- Market Cap $243M
- Description
- Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...